Loading
Chronic Obstructive Pulmonary Disease (COPD) Research / Pulmonary Hypertension Research and Treatments · Journal article
Current Opinion in Pulmonary Medicine · September 9, 2026
A consensus or society position rather than new primary data.
This narrative review identifies sleep-disordered breathing as an increasingly recognized but underdiagnosed contributor to WHO Group 3 pulmonary hypertension and outlines multifactorial mechanisms and treatment options. The authors emphasize that positive airway pressure therapy remains the cornerstone treatment and recommend prioritizing prospective trials to evaluate emerging modalities such as glucagon-like peptide-1 agonists, bariatric surgery, and standardization of hypoxic burden as a clinical endpoint.
Journal article. Patients with sleep-disordered breathing and pulmonary hypertension (WHO Group 3).
Mechanisms of SDB-related PH include recurrent nocturnal hypoxemia, altered intrathoracic pressures, and obesity-driven metabolic and inflammatory dysregulation Positive airway pressure therapy remains cornerstone treatment; mandibular advancement devices and hypoglossal nerve stimulation offer viable alternatives Hypoxic burden, rather than apnea-hypopnea index alone, is increasingly recognized as a better predictor for cardiovascular and pulmonary vascular outcomes
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should recognize SDB as an underdiagnosed contributor to pulmonary hypertension and prioritize early identification and positive airway pressure therapy where indicated. Hypoxic burden should be considered a more informative metric than apnea-hypopnea index alone when assessing cardiovascular risk in SDB patients.
A narrative review synthesizing epidemiology, pathophysiology, and current evidence for treatment of sleep-disordered breathing-related pulmonary hypertension, offering clinical recommendations but not reporting original trial data.
Clinicians should recognize SDB as an underdiagnosed contributor to pulmonary hypertension and prioritize early identification and positive airway pressure therapy where indicated. Hypoxic burden should be considered a more informative metric than apnea-hypopnea index alone when assessing cardiovascular risk in SDB patients.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
PURPOSE OF REVIEW: Sleep-disordered breathing (SDB) is an increasingly recognized contributor to WHO Group 3 pulmonary hypertension (PH). This review examines the epidemiology and pathophysiology linking SDB to PH, evaluates the evidence base for sleep-directed therapies in modifying pulmonary hemodynamics, and highlights emerging treatment modalities that may be able to alter disease course. RECENT FINDINGS: The mechanisms underlying SDB-related PH are multifactorial, including recurrent nocturnal hypoxemia, altered intrathoracic pressures, and obesity-driven metabolic and inflammatory dysregulation. Positive airway pressure therapy remains the cornerstone of treatment of SDB-related PH, though mandibular advancement devices and hypoglossal nerve stimulation offer viable alternatives. Hypoxic burden, rather than apnea-hypopnea index alone, is increasingly recognized as a better predictor for cardiovascular and pulmonary vascular outcomes in SDB. Long-term oxygen therapy provides hemodynamic benefit in patients with resting hypoxemia, though evidence is limited in those with isolated nocturnal desaturation. SUMMARY: SDB is an underdiagnosed and clinically important contributor to PH. Early identification and treatment, particularly with positive airway pressure therapy when indicated, can meaningfully reduce pulmonary arterial pressures. Future research should prioritize prospective trials examining the direct impact of glucagon-like peptide-1 receptor agonists and bariatric surgery on pulmonary hemodynamics and standardize the use of hypoxic burden as a clinical endpoint.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.